Trending...
- Are Productions Missing the Full Opportunities of Social Media Marketing?
- Legacy Gospel Series Project - New Previously Unreleased Recordings
- Obtain a USCG Captain's License During COVID-19
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
- Human Platelet Isolation Assay Kit
- San Jose: FLASH REPORT #149 - COVID-19 Response and Recovery
- San Francisco: Mayor London Breed Announces $500 Stimulus for Lower-Wage Workers and Families
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Infinity Q Capital Management LLC and Encourages Investors with Losses of $100,000 to Contact the Firm
- Get ready for Spring Break with a poem/potential song lyrics called "The New Coronavirus Blues"
Filed Under: Business
0 Comments
Latest on The Californer
- San Jose: Draft IS/Addendum: Our Lady of La Vang Church (SP19-028)
- San Jose: Draft IS/Addendum: 645 Horning Street Gas Station, Food, and Storage Project (PDA16-027-02)
- San Francisco Moves to Phase 1B of COVID-19 Vaccinations, Expands Eligibility to Educators, Child Care, Emergency Services, Food and Agriculture Workers
- All-new Virtual Music Lounge Turntable Adds Amanda Levensohn as Creative Director
- Honorary Oscar-Winner Charles Burnett brings his award winning film on COVID-19 / Black Hollywood to the Prestigious Pan African 2021 Film Festival
- In a year of recession, Lantek closes 2020 with record sales figures and customer numbers
- SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ebix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Emmy Nominated Television Producer, Erika Bryant To Release New Book Titled Doing It Scared
- The 2021 Encore Gospel Celebration of Unity Virtual Concert a must see star-studded event
- New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
- The Koedo Kawagoe Spring Festival Celebrates the Arrival of Springtime in Kawagoe, Japan
- Dropbox, Inc. Announces Upsize and Pricing of $1.306 Billion Convertible Senior Notes Offering
- Santa Monica Democratic Club Votes Unanimously to Approve Resolution for Columbia Sussex to Cease Future Operations in City, as Labor Dispute with UNITE HERE Local 11 Enters Fifth Year
- Long Beach: 58% of Seniors Vaccinated
- How to Get Product Testimonial Videos Very Quickly
- Aaron's Energy: An Unexpected Journey Through Grief and the Afterlife With My Brilliant Son
- California: Governor Newsom Announces Appointments 2.23.21
- Blume TV launches on Roku in 12 countries across Latin America
- Sulfated Glycosaminoglycans Assay Kit
- Veteran Prosecutor Jimmie Wilson, Running for Alameda County District Attorney on Platform of Accountability, Fairness and Transparency